XML 32 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity
 3 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Shareholders' Equity
10. Shareholders' Deficit
During the three months ended September 30, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares.
During June of fiscal year 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase of $500 million. We received an initial delivery of 4.6 million common shares using a reference price of $87.18. The program concluded on August 16, 2023 at a volume weighted average price per common share of $91.15 resulting in a final delivery of 0.9 million common shares.
During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares.
We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
Accumulated Other Comprehensive Loss
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023$(137)$(14)$(151)
Other comprehensive loss, before reclassifications(11)(1)(12)
Amounts reclassified to earnings— (2)(2)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $3 million
(11)(3)(14)
Balance at September 30, 2023$(148)$(17)$(165)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive loss, before reclassifications(58)(2)(60)
Amounts reclassified to earnings— (2)(2)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7 million
(58)(4)(62)
Balance at September 30, 2022$(160)$(16)$(176)